O
LAB icon

OrbiMed’s Standard BioTools LAB Stock Holding History

OrbiMed’s Portfolio LAB Stock Details LAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-3,819,348
Closed -$15M – 156
2021
Q4 		$15M Sell
3,819,348
-780,223
-17% -$3.65M 0.19% 99
2021
Q3 		$30.3M Sell
4,599,571
-62,300
-1% -$410K 0.33% 78
2021
Q2 		$28.7M Buy
4,661,871
+62,300
+1% +$333K 0.29% 81
2021
Q1 		$20.8M Buy
4,599,571
+707,225
+18% +$3.88M 0.19% 98
2020
Q4 		$23.4M Buy
3,892,346
+338,643
+10% +$2.22M 0.2% 95
2020
Q3 		$26.4M Buy
3,553,703
+646,603
+22% +$4.46M 0.33% 78
2020
Q2 		$11.7M Buy
+2,907,100
New +$10.1M 0.16% 93
2018
Q4 		– Sell
-1,077,801
Closed -$8.07M – 143
2018
Q3 		$8.07M Sell
1,077,801
-505,899
-32% -$3.6M 0.1% 117
2018
Q2 		$9.44M Hold
1,583,700
– – 0.11% 113
2018
Q1 		$9.25M Hold
1,583,700
– – 0.11% 107
2017
Q4 		$9.33M Sell
1,583,700
-162,400
-9% -$889K 0.12% 104
2017
Q3 		$8.8M Hold
1,746,100
– – 0.08% 109
2017
Q2 		$7.05M Hold
1,746,100
– – 0.07% 106
2017
Q1 		$9.94M Hold
1,746,100
– – 0.11% 97
2016
Q4 		$12.7M Hold
1,746,100
– – 0.16% 79
2016
Q3 		$14M Hold
1,746,100
– – 0.16% 88
2016
Q2 		$15.8M Hold
1,746,100
– – 0.16% 81
2016
Q1 		$14.1M Sell
1,746,100
-703,800
-29% -$5.08M 0.15% 72
2015
Q4 		$26.5M Hold
2,449,900
– – 0.24% 67
2015
Q3 		$19.9M Hold
2,449,900
– – 0.2% 74
2015
Q2 		$59.3M Buy
2,449,900
+313,700
+15% +$9.9M 0.5% 51
2015
Q1 		$89.9M Hold
2,136,200
– – 0.77% 40
2014
Q4 		$72.1M Buy
2,136,200
+36,000
+2% +$1.02M 0.69% 40
2014
Q3 		$51.5M Buy
2,100,200
+238,000
+13% +$6.69M 0.54% 47
2014
Q2 		$54.7M Buy
1,862,200
+415,000
+29% +$13.3M 0.64% 43
2014
Q1 		$63.8M Buy
1,447,200
+1,192
+0.1% +$52.4K 0.78% 40
2013
Q4 		$55.4M Buy
1,446,008
+29,400
+2% +$866K 0.81% 40
2013
Q3 		$31.1M Buy
1,416,608
+153,900
+12% +$3.02M 0.55% 43
2013
Q2 		$22M Buy
+1,262,708
New +$22.2M 0.47% 44

Other funds holding LAB

ICM
Indaba Capital Management San Francisco, California $33.8M AUM 33.83% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NIM
Needham Investment Management New York $1.96B AUM 101.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

OrbiMed's LAB Position: Q1 2022 in Review

OrbiMed sold out of Standard BioTools (LAB) in Q1 2022, closing a stake of 3,819,348 shares — an estimated $15M sold.

OrbiMed first reported a position in LAB in Q2 2013 and held it in 29 quarters. The position peaked at $89.9M in Q1 2015. 109 funds tracked by Wall St. Rank hold LAB as of Q1 2022.

  • OrbiMed reported no remaining Standard BioTools position as of Q1 2022 after selling out during the quarter.
  • OrbiMed sold 3,819,348 Standard BioTools shares in Q1 2022, an estimated $15M.
  • OrbiMed first reported a position in Standard BioTools in Q2 2013 and held it in 29 quarters.
  • OrbiMed's Standard BioTools position peaked at $89.9M in Q1 2015.
  • 109 funds tracked by Wall St. Rank held Standard BioTools as of Q1 2022.

Based on OrbiMed's 13F filing for Q1 2022, filed 16 May 2022.